COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prevention of Melasma Relapse During Summertime

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02061839
Recruitment Status : Completed
First Posted : February 13, 2014
Last Update Posted : February 13, 2014
Information provided by (Responsible Party):
Centre de Pharmacologie Clinique Applique a la Dermatologie

Brief Summary:
Main objective is to show that a photoprotective sunscreen having a protection against the visible light is more effective than a sunscreen having the same UVA AND UVB protection but with a low (weak) protection against the visible, to prevent the relapses of the melasma during the summertime.

Condition or disease Intervention/treatment Phase
Melasma Other: Sunscream with visible light protection Other: Sunscream Not Applicable

Detailed Description:

40 melasma affected women will be included and randomized in two parallel groups (one group protected by a UVA+UVB+visible extended sunscreen and one group group protected by a UVA+UVB sunscreen).

There will be 3 visits: Baseline, T2.5months and T5months (final visit).

Products application frequency: twice daily(morning and afternoon) and additional applications every 2 hours in case of solar exposure.

Main evaluation criterion: the MASI score assessed from standardized photographs (system VISIA, Canfield Scientific, USA) at Baseline, middle and end of study.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: Prevention of Melasma Relapse During Summertime
Study Start Date : March 2013
Actual Primary Completion Date : August 2013
Actual Study Completion Date : October 2013

Arm Intervention/treatment
Experimental: Teinted sunscream
UVA, UVB and visible light protection (exactly the same UVA and UVB protection as the comparator)
Other: Sunscream with visible light protection
Active Comparator: Regular sunscream
UVA and UVB protection
Other: Sunscream

Primary Outcome Measures :
  1. Comparison between MASI scores before prevention treatment and after 6 months [ Time Frame: 6 months ]
    MASI scores are evaluated by two physicians blinded to the treatment received on standardized pictures taken before treatment and after 6 months of summer period

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Melasma

Exclusion Criteria:

  • Other pigmentary disorders associated (including PIH)
Layout table for additonal information
Responsible Party: Centre de Pharmacologie Clinique Applique a la Dermatologie Identifier: NCT02061839    
Other Study ID Numbers: 2013-A00073-42
First Posted: February 13, 2014    Key Record Dates
Last Update Posted: February 13, 2014
Last Verified: February 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Pigmentation Disorders
Skin Diseases